Arcosa (ACA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, Arcosa (ACA) reported revenue of $797.8 million, up 24.6% over the same period last year. EPS came in at $1.56, compared to $0.91 in the year-ago quarter.The reported revenue represents a surprise of +2.68% over the Zacks Consensus Estimate of $776.95 million. With the consensus EPS estimate being $1.33, the EPS surprise was +17.29%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Arcosa performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Construction Products: $387.5 million compared to the $386.36 million average estimate based on two analysts. The reported number represents a change of +45.7% year over year.Revenues- Transportation Products: $99.3 million compared to the $93.74 million average estimate based on two analysts. The reported number represents a change of +4.4% year over year.Revenues- Engineered Structures: $311 million compared to the $296.88 million average estimate based on two analysts. The reported number represents a change of +11.3% year over year.View all Key Company Metrics for Arcosa here>>>Shares of Arcosa have returned +0.6% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Arcosa, Inc. (ACA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks